Spyre Therapeutics (NASDAQ: SYRE) posts trial update, new CCO via 8-K

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. furnished a current report describing a new press release and an updated corporate presentation made available on its website. These materials include updates on the company’s ongoing clinical trials and the appointment of Kate Tansey Chevlen as Chief Commercial Officer.

The press release (Exhibit 99.1) and the January 2026 corporate presentation (Exhibit 99.2) are provided as exhibits and are treated as furnished rather than filed under securities laws, which affects how they are incorporated into other regulatory documents.

false 0001636282 0001636282 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

SPYRE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-37722		46-4312787
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
221 Crescent Street
Building 23
Suite 105
Waltham, MA				02453
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 651-5940

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per Share		SYRE		The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) and posted an updated corporate presentation (the “Corporate Presentation”) on its website. The Press Release and the Corporate Presentation include, without limitation, updates on the Company’s ongoing clinical trials and the appointment of Kate Tansey Chevlen as Chief Commercial Officer. Copies of the Press Release and Corporate Presentation are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release of the Company, dated January 12, 2026
99.2		Corporate Presentation (January 2026)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						SPYRE THERAPEUTICS, INC.
Date: January 12, 2026				By:		/s/ Cameron Turtle
						Cameron Turtle
						Chief Executive Officer

FAQ

What did Spyre Therapeutics (SYRE) disclose in this 8-K filing?

Spyre Therapeutics disclosed that it issued a press release and posted an updated corporate presentation providing updates on its ongoing clinical trials and management team.

What management change did Spyre Therapeutics (SYRE) report?

The company reported the appointment of Kate Tansey Chevlen as Chief Commercial Officer, as highlighted in its press release and corporate presentation.

Where can investors find the new Spyre Therapeutics (SYRE) materials?

The updated corporate presentation is posted on the company’s website, and both the press release (Exhibit 99.1) and the January 2026 corporate presentation (Exhibit 99.2) are attached as exhibits to the 8-K.

Are the Spyre Therapeutics (SYRE) press release and presentation considered filed with the SEC?

The company states that the information in Item 7.01, including Exhibits 99.1 and 99.2, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

On which exchange is Spyre Therapeutics (SYRE) common stock listed?

Spyre Therapeutics’ common stock, par value $0.0001 per share, trades on The Nasdaq Stock Market LLC (Nasdaq Global Select Market) under the symbol SYRE.

What exhibits are included with this Spyre Therapeutics (SYRE) 8-K?

The exhibits include a press release dated January 12, 2026 (99.1), a January 2026 corporate presentation (99.2), and a cover page interactive data file (104).